Immuneering Corporation (IMRX)

Immuneering Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.32	2.08	2.31
Revenue Growth (YoY)	-	-	-84.76%	-10.02%	20.41%
Cost of Revenue	-	-	0.16	1.15	1.28
Gross Profit	-	-	0.16	0.93	1.03
Selling, General & Admin	16.08	16.76	15.61	8.27	3.11
Research & Development	47.96	41.62	36.27	26.54	15
Operating Expenses	64.07	58.41	51.9	34.81	18.11
Operating Income	-64.07	-58.41	-51.74	-33.89	-17.08
Interest & Investment Income	2.59	3.61	1.01	0.17	0.04
Other Non Operating Income (Expenses)	0.18	0.32	0.05	0	-
EBT Excluding Unusual Items	-61.3	-54.49	-50.68	-33.71	-17.04
Gain (Loss) on Sale of Investments	0.26	1.02	0.17	-0.13	-
Pretax Income	-61.04	-53.47	-50.51	-33.84	-17.04
Income Tax Expense	-	-	-	-0.31	-
Net Income	-61.04	-53.47	-50.51	-33.54	-17.04
Net Income to Common	-61.04	-53.47	-50.51	-33.54	-17.04
Shares Outstanding (Basic)	30	28	26	14	5
Shares Outstanding (Diluted)	30	28	26	14	5
Shares Change (YoY)	5.51%	7.69%	93.84%	175.00%	-
EPS (Basic)	-2.04	-1.88	-1.91	-2.46	-3.44
EPS (Diluted)	-2.04	-1.88	-1.91	-2.46	-3.44
Free Cash Flow	-55.08	-49.31	-44.84	-30.91	-14.67
Free Cash Flow Per Share	-1.84	-1.74	-1.70	-2.27	-2.96
Gross Margin	-	-	50.11%	44.56%	44.61%
Operating Margin	-	-	-16325.77%	-1629.17%	-739.01%
Profit Margin	-	-	-15937.29%	-1612.33%	-737.17%
Free Cash Flow Margin	-	-	-14148.44%	-1486.17%	-634.83%
EBITDA	-63.69	-58.06	-51.47	-33.84	-17.06
D&A For EBITDA	0.39	0.35	0.28	0.05	0.02
EBIT	-64.07	-58.41	-51.74	-33.89	-17.08

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q